MIRA INFORM REPORT

 

 

Report No. :

323741

Report Date :

28.05.2015

 

IDENTIFICATION DETAILS

 

Name :

ROMIKIN SA

 

 

Registered Office :

Paraguay 1535 C1061 ABC Buenos Aires, Capital Federal

 

 

Country :

Argentina

 

 

Date of Incorporation :

10.10.1986

 

 

Legal Form :

Sociedad Anónima

 

 

Line of Business :

Subject develops and manufactures products for the life sciences sector.

 

 

No. of Employee :

90

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Argentina

C1

C1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

ARGENTINA ECONOMIC OVERVIEW

 

Argentina benefits from rich natural resources, a highly literate population, an export-oriented agricultural sector, and a diversified industrial base. Although one of the world's wealthiest countries 100 years ago, Argentina suffered during most of the 20th century from recurring economic crises, persistent fiscal and current account deficits, high inflation, mounting external debt, and capital flight. A severe depression, growing public and external indebtedness, and an unprecedented bank run culminated in 2001 in the most serious economic, social, and political crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ SAA declared a default - at the time the largest ever - on the government's foreign debt in December of that year, and abruptly resigned only a few days after taking office. His successor, Eduardo DUHALDE, announced an end to the peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60% of Argentines under the poverty line. Real GDP rebounded to grow by an average 8.5% annually over the subsequent six years, taking advantage of previously idled industrial capacity and labor, an audacious debt restructuring and reduced debt burden, excellent international financial conditions, and expansionary monetary and fiscal policies. Inflation also increased, however, during the administration of President Nestor KIRCHNER, which responded with price restraints on businesses, as well as export taxes and restraints, and beginning in 2007, with understating inflation data. Cristina FERNANDEZ DE KIRCHNER succeeded her husband as President in late 2007, and the rapid economic growth of previous years began to slow sharply the following year as government policies held back exports and the world economy fell into recession. The economy in 2010 rebounded strongly from the 2009 recession, but has slowed since late 2011 even as the government continued to rely on expansionary fiscal and monetary policies, which have kept inflation in the double digits. The government expanded state intervention in the economy throughout 2012. In May 2012 the Congress approved the nationalization of the oil company YPF from Spain's Repsol. The government expanded formal and informal measures to restrict imports during the year, including a requirement for pre-registration and pre-approval of all imports. In July 2012 the government also further tightened currency controls in an effort to bolster foreign reserves and stem capital flight. During 2013, the government continued with a mix expansionary fiscal and monetary policies and foreign exchange and imports controls to limit the drain in Central Bank foreign reserves, which nevertheless dropped US $12 billion during the year. GDP grew 3% and inflation remained steady at 25%, according to private estimates. In October 2013, the government settled long-standing international arbitral disputes (including with three US firms) dating back to before and following the 2001-02 Argentine financial crisis. In early 2014, the government embraced some orthodox economic policies. It devalued the peso 20%, substantially tightened monetary and fiscal policies, and took measures to mend ties with the international financial community, including: engaging with the IMF to improve its economic data reporting, reaching a compensation agreement with Repsol for the expropriation of YPF, and presenting a proposal to pay its arrears to the Paris Club. Nevertheless, the government in July 2014 defaulted again on its external debt after it failed to reach an agreement with US holdout creditors. The government’s delay in reaching a settlement and the continuation of interventionist policies are contributing to a prolonged recession.

 

Source : CIA

 

 

 

STATUTORY INFORMATION

 

Legal Name:

ROMIKIN SA

Trade Name:

ROMIKIN 

CUIT:

30-61116362-9

Date Created:

1986

Date Incorporated:

10/10/1986

Legal Address:

Paraguay 1535
C1061 ABC
Buenos Aires, Capital Federal
Argentina.

Operative Address:

Paraguay 1535
C1061 ABC
Buenos Aires, Capital Federal
Argentina.

Telephone:

54 11 4872 1200

Fax:

54 11 4872 1201

Legal Form:

Sociedad Anónima

Email:

romikin@chemogroup.com

Registered in:

AGENCIA NRO 11
CARLOS PELLEGRINI N° 685 1° PISO
1009 CIUDAD AUTONOMA BUENOS AIRES

Website:

www.romikin.com.ar

Contact:

Hugo Daniel Valerio, President

Staff:

90

Activity:

Medical Equipment & Supply Wholesalers Industry

 

 

BANKS

According to Argentinian Central Bank, the company maintains credit lines with the following banks:

BANK

AMOUNT IN AR$

BANCO PATAGONIA S.A.

2707,4

BANCO CREDICOOP COOPERATIVO LIMITADO

2283,1

AMERICAN EXPRESS ARGENTINA S.A.

283,9

BANCO DE GALICIA Y BUENOS AIRES S.A.

8,7

 

 

 

According to the classification of banking relations of Argentina,
the company operates with level: 1.
This is the highest classification in the system. It means that the  company/person is fulfilling correctly its current Credit
obligations.

 

 

Rejected Checks:

 

95388201 30/09/2014

11.982,16

95388203 30/09/2014

1.789,04

95388204 30/09/2014

6.489,98

95388208 30/09/2014

218.500,00

 

 

HISTORY

 

 

Romikin is CHEMO sales office in Argentina. It was established in 1986 and also has competencies in Uruguay, Paraguay and Bolivia.

 

 

PRINCIPAL ACTIVITY

 

 

Romikin develops and manufactures products for the life sciences sector.

Products/Services description:

It focuses on the research and development of independent industrial synthetic methods for the production of active pharmaceutical ingredients (API), including PPI, steroids, macrolides, and sartans; and production of finished dosage forms, such as antiulcerants, antivirals, anitbiotics, contraceptives and HRT, and antifungals, as well as products for cholesterol, insomnia, asthma, and COPD. The company also manufactures and markets active substances that are used in the manufacture of veterinary drugs, such as antibiotics, anthelmintics, anti-inflammatory products, antiparasities, and coccidiostatic and chemotherapeutical drugs; and insecticides, fungicides, herbicides, and micronutrients for agrochemical formulations.

Brands:

RK ROMIKIN
TECNOSUMA
VP VETPHARMA

Sales are:

Wholesale

Clients:

SCAVONE HERMANOS SA
Paraguay

QUIMFA SA
Paraguay

Suppliers:

FERSINSA GB SA DE CV
Mexico

Operations area:

National and International

The company imports from

Mexico

The company exports to

Paraguay

The subject employs

90 employees

Payments:

Regular-on a 40 day basis (information taken from the Argentina Central Bank)

 

 

LOCATION

 

Headquarters :

Paraguay 1535
C1061 ABC
Buenos Aires, Capital Federal
Argentina.

Branches:

The company does not have branches

Industry:

Companies in this industry distribute professional medical equipment, instruments, and supplies to physicians, hospitals, and extended care facilities.

Demand depends on the number of people receiving medical treatment and advances in medical technology. The profitability of individual companies depends on merchandising and efficient delivery systems. Large companies have economies of scale in purchasing, as well as highly developed infrastructure that allow for efficient distribution. Small companies can compete effectively by specializing in a product line or by serving a local market.

Major products include medical and surgical instruments and equipment (about 55 percent of revenue); supplies (about 25 percent); and orthopedic and prosthetic appliances (10 percent). Other products include dental and veterinary equipment and supplies. Some companies carry more than 250,000 stock-keeping units (SKUs), while others specialize in niche markets and may carry only a few different items to serve a local market’s specific needs.

 

 

GROUP STRUCTURE AND SUBSIDIARY COMPANIES

 

Listed at the stock exchange:

NO

Capital:

AR$ 255.618.484

Shareholders:

The company is a subsidiary of:

CHEMO Ibérica Madrid
Edificio Ofipinar
C/ Caleruega, 102 6ºth floor.
28033 Madrid, Spain.
Tel: +34 91 302 15 60
Fax: + 34 91 766 89 63

Management:

Hugo Daniel Valerio, President
Jorge RubéN Castro, Vicepresident
Carlos Alberto CáMpora, Fiduciary
Manuel Alberto Sobrado, Director
Emilio Daniel Papariello, Subdirector
MaríA Florencia Bin Astigarraga, Subdirector
Jorge AndréS Sierra

Related Companies:

CHEMO Lugano Branch
via F. Pelli, 17
6901 – Lugano, Switzerland.
Tel: +41 91 973 21 01
Fax: +41-91 973 21 06
lugano@chemogroup.com

Chem - East
Lajos V. 48-66
Bldg "E" 5th floor
1036 Budapest, Hungary.
Tel: +36-1-2 750336/37/38
Fax: +36- 1-2 753219
chemeast@chemogroup.com

CHEMO Indian Branch
602, 6th Floor,
Mahavir Chambers Liberty Road
Hyderabad - 500 029
Andhra Pradesh, India
Tel/fax: + 91 40 23223605/08/09/10
Indian@chemogroup.com

CHEMO Asia
Hua Du building, 28th floor, C left
Zhang Yang road, 828-838
Shanghai
R.P. of China
Tel: + 86 21 50 81 23 58
+ 86 21 50 81 23 68
Fax: + 86 21 50 81 22 28
asia@chemogroup.com

Chemway
Hua Du Mansion, 9th Floor
Zhang Yang road, 828-838
Shanghai
R.P. of China
Phone: + 86 21 50 81 32 28
Fax:+ 86 21 50 81 22 28
asia@chemogroup.com

Chemessentia
Via Bovio 6
28100, Novara, Italia.
Phone: + 39 0321 650255
Fax: + 39 0321 479200
info@chemessentia.it
CHEMO Brasil
Rua Sampaio Viana Nº 253 –conj.14 and 15
São Pablo, Brasil
Phone: + 55 11 3052 1063
Fax: + 55 11 3052 1064
administracao@chemodobrasil.com.br

 

 

FINANCIAL INFORMATION

 

 

This is a private company which does not make its financial figures public. The following information has been provided by outside sources.

 

 

USD 2013

 

Revenue

AR$ 20 000 000

Cash Flow

Good

 

 

Exports Annual FOB DOLLAR

 

2014

1.342.601

2013

878.268

2012

243.719

2011

356.115

2010

130.190

 

 

LEGAL FILINGS

 

 

There are no legal connected to the subject

 

 

SUMMARY

 

 

Romikin is CHEMO sales office in Argentina. It was established in 1986 and also has competencies in Uruguay, Paraguay and Bolivia.

 

The Company has a médium-large sized structure and is part of a large group headquartered in Spain.

 

The company is well established in business. However; it shows high debts and some rejected checks. This may be related to the large sized of the company.

 

 

RISK INFORMATION

 

 

 

DEBTS

High-Controlled

PAYMENTS

Regular

CASH FLOW

Normal

STATUS

Active

 

 

INTERVIEW

 

NAME

Andrea

POSITION

Administrative 

COMMENTS

The person contacted confirmed address and group. She refused to provide more information. 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.63.95

UK Pound

1

Rs.98.64

Euro

1

Rs.69.86

 

 

INFORMATION DETAILS

 

Analysis Done by :

RAS

 

 

Report Prepared by :

ANK

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.